Responses
Ovarian cancer
2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.